News

November 7, 2022

Navrogen Enters into CRADA with The U.S. National Cancer Institute for the Clinical Development of NAV-001, an Anti-Mesothelin Antibody-Drug Conjugate

Navrogen announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with researchers at the U.S. National Cancer Institute (NCI), part of the National Institutes...

 

Read More

March 28, 2022

Navrogen Presents Preclinical Data on Its NAV-001 Antibody-Drug Conjugate Program at the 12th World ADC Conference in London

Navrogen has presented new preclinical data on its NAV-001 antibody-drug conjugate (ADC) program at the 12th World ADC Conference in London, UK, on Wednesday, March 30th.

 

Read More

November 30, 2021

Navrogen Announces Publication of its Block-Removed Immunoglobulin Technology (BRITE) to Optimize Rituximab Activity in Humoral Immunosuppressed Cancers

Navrogen announced today the publication of preclinical data regarding application of its proprietary Block-Removed Immunoglobulin Technology (BRITE) to enhance the efficacy of the CD20-targeting rituximab antibody in the presence...

 

Read More

September 13, 2021

Navrogen Enters into CRADA with USAMRIID to Test Proprietary Small Molecule NK Cell Activators Against SARS-COV-2 Infection

Navrogen announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with researchers at The United States Army Medical Research Institute of Infectious Diseases (USAMRIID)....

 

Read More

August 17, 2021

Navrogen Inc. and Tavotek Biotherapeutics Announce Strategic Collaboration to Improve Therapeutic Efficacy of Antibody Pipeline Agents

Navrogen and Tavotek will collaborate on the development of future Tavotek oncology assets while utilizing Navrogen’s proprietary screening technology to identify mAb leads that are susceptible to Humoral Immuno-Oncology...

 

Read More

August 9, 2021

Navrogen Closes $3.0M Seed Financing to Advance Its Preclinical Pipeline Targeting Humoral Immunosuppressed Cancers and Immune-Related Disorders

Navrogen, Inc., a privately held preclinical biotechnology company, announced today that it has raised $3.0M from an equity financing to support its Humoral Immuno-Oncology (HIO) discovery platform and preclinical...

 

Read More